U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H21N3O
Molecular Weight 307.3903
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZOLPIDEM

SMILES

Cc1ccc(cc1)-c2c(CC(=O)N(C)C)n3cc(C)ccc3n2

InChI

InChIKey=ZAFYATHCZYHLPB-UHFFFAOYSA-N
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C19H21N3O
Molecular Weight 307.3903
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zolpidem is usually used for the treatment of insomnia as a hypnotic drug. It was also suggested to be effective in the treatment of dystonia in some studies. Zolpidem can be one of useful alternative pharmacological treatments for blepharospasm. Zolpidem interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem in vitro binds the BZ1 receptor preferentially with a high affinity ratio of the α1/α5 subunits. This selective binding of zolpidem on the BZ1 receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep in human studies of zolpidem tartrate at hypnotic doses.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AMBIEN

Approved Use

Ambien (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Ambien has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14)

Launch Date

724464000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
121 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
59 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.5 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
26 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.5%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
7.5%
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ZOLPIDEM unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Other AEs: Psychiatric symptom, Gastrointestinal disorder (NOS)...
Other AEs:
Psychiatric symptom (6 patients)
Gastrointestinal disorder (NOS) (6 patients)
Nervous system disorder NOS (5 patients)
Sources:
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
unhealthy, 68 years
Health Status: unhealthy
Age Group: 68 years
Sex: F
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Drowsiness, Vertigo...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1.1%)
Vertigo (0.8%)
Amnesia (0.5%)
Nausea (0.5%)
Headache (0.4%)
Fall (0.4%)
Sources:
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Drowsiness, Dizziness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (0.5%)
Dizziness (0.4%)
Headache (0.5%)
Nausea (0.6%)
Vomiting (0.5%)
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 10 patients)
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Somnolence, Coma...
AEs leading to
discontinuation/dose reduction:
Somnolence (100%)
Coma (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nervous system disorder NOS 5 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Gastrointestinal disorder (NOS) 6 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Psychiatric symptom 6 patients
0.5 mg/kg single, oral
Highest studied dose
Dose: 0.5 mg/kg
Route: oral
Route: single
Dose: 0.5 mg/kg
Sources:
unhealthy, 2 - 12 years
Health Status: unhealthy
Age Group: 2 - 12 years
Sex: M+F
Sources:
Death grade 5, 1 patient
Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
unhealthy, 68 years
Health Status: unhealthy
Age Group: 68 years
Sex: F
Sources:
Fall 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 0.4%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Amnesia 0.5%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 0.5%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vertigo 0.8%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Drowsiness 1.1%
Disc. AE
50 mg 1 times / day steady, oral
Highest studied dose
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Dizziness 0.4%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Drowsiness 0.5%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Headache 0.5%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Vomiting 0.5%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Nausea 0.6%
Disc. AE
90 mg 1 times / day steady, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Death grade 5, 10 patients
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Coma 1 patient
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Somnolence 100%
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: A single-dose interaction study with zolpidem tartrate 10 mg and rifampin (CYP3A4 inducer) 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), Cmax (-58%), and T1/2 (-36 %) of zolpidem together
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Development and modulation of GABA(A) receptor-mediated neurotransmission in the CA1 region of prenatally protein malnourished rats.
2001
[Correction of sleep disorders and efficacy of antihypertensive monotherapy in elderly patients: use of ivadal].
2001
Assessing the effects of an intervention by a pharmacist on prescribing and administration of hypnotics in nursing homes.
2001 Dec
Delirium associated with zolpidem.
2001 Dec
[Zolpidem: the risk of tolerance and dependence according to case reports, systematic studies and recent molecularbiological data].
2001 Dec
Diminished allopregnanolone enhancement of GABA(A) receptor currents in a rat model of chronic temporal lobe epilepsy.
2001 Dec 1
Functional analysis of GABA(A) receptors in nucleus tractus solitarius neurons from neonatal rats.
2001 Dec 7
Arousal from a semi-comatose state on zolpidem.
2001 Oct
Zolpidem in restless legs syndrome.
2002
Tolerability of hypnosedatives in older patients.
2002
Melatonin for the prevention and treatment of jet lag.
2002
[Unexplained increase in aminotransferases and obstructive sleep apnea syndrome].
2002 Apr
Hallucinations and Zolpidem.
2002 Aug
Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.
2002 Aug 1
The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem.
2002 Aug 15
[Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent].
2002 Feb
Discriminative stimulus effects of benzodiazepine (BZ)(1) receptor-selective ligands in rhesus monkeys.
2002 Feb
Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem.
2002 Feb
[Epileptic seizures as a sign of abstinence from chronic consumption of zolpidem].
2002 Feb 1-15
Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors.
2002 Feb 15
Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome.
2002 Feb 26
Fibromyalgia: patient perspectives on symptoms, symptom management, and provider utilization.
2002 Jan
Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study.
2002 Jan
Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia.
2002 Jan
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography.
2002 Jul
[Abuse, tolerance and dependence of zolpidem: three case reports].
2002 Jul-Aug
Early cerebral activities of the environmental estrogen bisphenol A appear to act via the somatostatin receptor subtype sst(2).
2002 Jun
Zolpidem, vascular headache, and hallucinations in an adolescent.
2002 Jun
"As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting.
2002 Mar
The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations.
2002 Mar
Soyka M, Bottlender R, Möller H-J; Epidemiological evidence for a low abuse potential of zolpidem; Pharmacopsychiatry 2000, 33: 138 - 141.
2002 Mar
Selective actions on sleep or anxiety by exploiting GABA-A/benzodiazepine receptor subtypes.
2002 Mar
Zolpidem in progressive supranuclear palsy.
2002 Mar
Sleep disorders and daytime sleepiness in state police shiftworkers.
2002 Mar-Apr
Clinical syndrome associated with zolpidem ingestion in dogs: 33 cases (January 1998-July 2000).
2002 Mar-Apr
Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.
2002 May
Role of GABAA/benzodiazepine receptors containing alpha 1 and alpha 5 subunits in the discriminative stimulus effects of triazolam in squirrel monkeys.
2002 May
Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells.
2002 May
GABAA-benzodiazepine receptor complex ligands and stress-induced hyperthermia in singly housed mice.
2002 May
Rifampin and rifabutin drug interactions: an update.
2002 May 13
Adaptive time-frequency parametrization in pharmaco EEG.
2002 May 30
Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions.
2002 May 8
Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons.
2002 Oct
Functional characterization of GABA(A) receptors in neonatal hypothalamic brain slice.
2002 Oct
Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use.
2002 Oct
Relative picrotoxin insensitivity distinguishes ionotropic GABA receptor-mediated IPSCs in hippocampal interneurons.
2002 Sep
GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem.
2002 Sep
Mechanisms of anabolic androgenic steroid modulation of alpha(1)beta(3)gamma(2L) GABA(A) receptors.
2002 Sep
Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes.
2002 Sep 13
Patents

Patents

Sample Use Guides

Dosage in Adults: the recommended initial dose is 5 mg for women and either 5 or 10 mg for men, taken only once per night immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. If the 5 mg dose is not effective, the dose can be increased to 10 mg. In some patients, the higher morning blood levels following use of the 10 mg dose increase the risk of next day impairment of driving and other activities that require full alertness. The total dose of AMBIEN (zolpidem tartrate) should not exceed 10 mg once daily immediately before bedtime. Ambien should be taken as a single dose and should not be readministered during the same night.
Route of Administration: Oral
Human embryonic kidney (HEK) 293 cells stably expressing recombinant α1β2γ2s GABA(A) receptors were exposed to zolpidem (1 and 10 μmol/L) for short-term (2 h daily for 1, 2, or 3 consecutive days) or long-term (continuously for 48 h). Radioligand binding studies were used to determine the parameters of [(3)H]flunitrazepam binding sites. A single (2 h) or repeated (2 h daily for 2 or 3 d) short-term exposure to zolpidem affected neither the maximum number of [(3)H]flunitrazepam binding sites nor the affinity. In both control and short-term zolpidem treated groups, addition of GABA (1 nmol/L-1 mmol/L) enhanced [(3)H]flunitrazepam binding in a concentration-dependent manner. The maximum enhancement of [(3)H]flunitrazepam binding in short-term zolpidem treated group was not significantly different from that in the control group. In contrast, long-term exposure to zolpidem resulted in significantly increase in the maximum number of [(3)H]flunitrazepam binding sites without changing the affinity. Furthermore, long-term exposure to zolpidem significantly decreased the ability of GABA to stimulate [(3)H]flunitrazepam binding.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:34:43 UTC 2021
Edited
by admin
on Fri Jun 25 20:34:43 UTC 2021
Record UNII
7K383OQI23
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZOLPIDEM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
ZOLPIDEM [INN]
Common Name English
ZOLPIDEM CIV
USP-RS  
Common Name English
SANVAL
Brand Name English
ZOLPIDEM [MI]
Common Name English
ZOLPIDEM [WHO-DD]
Common Name English
N,N,6-TRIMETHYL-2-P-TOLYL-IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE
Common Name English
ZOLPIDEM [VANDF]
Common Name English
IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE, N,N,6-TRIMETHYL-2-(4-METHYLPHENYL)-
Systematic Name English
ZOLPIDEM CIV [USP-RS]
Common Name English
Classification Tree Code System Code
WHO-VATC QN05CF02
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
NDF-RT N0000175759
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
DEA NO. 2783
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
WHO-ATC N05CF02
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
NCI_THESAURUS C29756
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
LIVERTOX 1053
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
Code System Code Type Description
PUBCHEM
5732
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
WIKIPEDIA
ZOLPIDEM
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
MERCK INDEX
M11661
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY Merck Index
CAS
82626-48-0
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
INN
5741
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
ChEMBL
CHEMBL911
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
FDA UNII
7K383OQI23
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
DRUG BANK
DB00425
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
DRUG CENTRAL
2870
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
LACTMED
Zolpidem
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
USP_CATALOG
1724893
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY USP-RS
EPA CompTox
82626-48-0
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
EVMPD
SUB00183MIG
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
MESH
C049109
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
IUPHAR
4348
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
RXCUI
39993
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000007570
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY Pyridines [Chemical/Ingredient]
NCI_THESAURUS
C62000
Created by admin on Fri Jun 25 20:34:43 UTC 2021 , Edited by admin on Fri Jun 25 20:34:43 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> NON-INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Route of Elimination PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY ORAL SPRAY, SL TABLET

EXTENDED-RELEASE TABLET

Route of Elimination PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC SPECIAL POPULATIONS
PHARMACOKINETIC
SPECIAL POPULATIONS
PHARMACOKINETIC
SPECIAL POPULATIONS
PHARMACOKINETIC
SPECIAL POPULATIONS
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC SPECIAL POPULATIONS
PHARMACOKINETIC
SPECIAL POPULATIONS
PHARMACOKINETIC
SPECIAL POPULATIONS
PHARMACOKINETIC